www.cnbc.com Open in urlscan Pro
23.78.2.126  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Business News and Finance
VIEW IN APP
MarketsBusinessInvestingTechPoliticsSelectMake It

Close the sidebar

WATCH LIVE
Health and Science


MODERNA SAYS NEW COVID VACCINE SHOWED STRONGER IMMUNE RESPONSE THAN CURRENT SHOT
IN STUDY

Published Tue, Mar 26 2024 11:25 AM EDTUpdated Tue, Mar 26 2024 1:02 PM EDT
Annika Kim Constantino
@annikakimc
WATCH LIVE
KEY POINTS
 * Moderna said a new version of its Covid vaccine triggered a stronger immune
   response against the virus than its current shot on the market in a
   late-stage trial. 
 * The results come as Moderna competes with rival Pfizer for more share of the
   Covid vaccine market and tries to diversify its revenue streams after the
   steep drop in demand for Covid products last year.
 * The biotech company's new "next-generation" shot offers the potential of a
   longer shelf life and is one component of its combination vaccine targeting
   Covid and the flu.

In this article

 * MRNA

A nurse fills a syringe with Moderna Covid-19 vaccine.
Fred Tanneau | Afp | Getty Images

Moderna on Tuesday said a new version of its Covid vaccine triggered a stronger
immune response against the virus than its current shot in a late-stage trial. 

The results come as Moderna competes with rival Pfizer for more share of the
Covid vaccine market and tries to diversify its revenue streams after the world
saw a plunge in demand for Covid products last year. Moderna's current Covid
vaccine, known as Spikevax, is its only commercially available product. 


Continue Reading

The biotech company's new shot could offer a longer shelf life and easier
storage than its Covid vaccine. 

Moderna's new shot is designed to last longer when refrigerated. That could make
the jab easier to distribute around the world, especially in developing
countries that may not have freezer capabilities. The company will accomplish
that by shortening the length of the mRNA strand in the vaccine, Moderna
previously told CNBC. 

The new shot is also a "critical component" of Moderna's combination vaccine
targeting Covid and the flu, the company said in a release. Both Moderna and
Pfizer have said that the convenience of receiving protection against two
viruses at once could encourage more people to get vaccinated against Covid. 

The phase three trial followed roughly 11,400 people ages 12 and older in the
U.S., U.K. and Canada. 

Moderna's new shot specifically triggered a higher immune response against
omicron subvariants BA.4 and BA.5 and the original strain of the virus than the
company's bivalent vaccine targeting those variants. The benefits were "most
acutely" seen in patients over the age of 65, who are also at highest risk of
severe illness from Covid. 




MORE CNBC HEALTH COVERAGE

 * Viking Therapeutics stock jumps more than 25% on promising weight loss pill
   data
 * Amgen wants in on the booming weight loss drug market — and it's taking a
   different approach
 * Medicare can now cover certain weight loss drugs in a big step for patients

The most common side effects were injection site pain, headache, fatigue, muscle
aches and chills, according to the company's release. Overall, Moderna said the
safety profile is similar to the approved vaccine Spikevax. 

A detailed analysis of the late-stage trial results will be presented at
Moderna's vaccines event for investors Wednesday. At the event, the company will
highlight other parts of its pipeline. 

Moderna is working to develop shots against the flu, cancer and other disease.
The company's shot against respiratory syncytial virus is expected to win Food
and Drug Administration approval in May.

Moderna has also said it plans to launch up to 15 products in the next five
years — a goal it first outlined during its annual research and development day
in September.


DON’T MISS THESE EXCLUSIVES FROM CNBC PRO

 * Friday's biggest analyst calls: Apple, Amazon, Tesla, Microsoft, Boeing,
   First Solar, Schwab & more
 * Citi says this ‘high risk’ but ‘attractive’ global stock has 280% upside
 * This AI stock could fall 50% and has an ‘exaggerated artificial intelligence
   narrative,’ Morningstar says
 * Morgan Stanley names 3 overlooked global tech stocks, giving one almost 100%
   upside

In this article

 * MRNA

Trending Now
 * 1
   26-year-old works 20 minutes a day—and brings in $462,000 a year from his
   Etsy side hustle
 * 2
   The 14 U.S. states where you can still afford to buy a home if you earn less
   than $75,000
 * 3
   Couple pays $1,600 a month for a 1-bedroom apartment in Brooklyn—they have
   150 plants: Look inside
 * 4
   Student loan borrowers could have up to $20,000 in interest forgiven as early
   as this fall
 * 5
   Trump tries to boost support for Truth Social as DJT stock tanks

View the full site


A circle with an upward arrow icon.Back to Top

© 2024 CNBC LLC. All Rights Reserved. A Division of NBCUniversal

Data is a real time snapshot *Data is delayed at least 15 minutes. Global
Business and Financial News, Stocks, Quotes, and Market Data, and Analysis.

Privacy Policy Do Not Sell My Personal Information CA Notice Terms of Service

Data also provided by